TrialESMO open2024

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.

M Saleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.